Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver ...

Achieved proof-of-mechanism for Wave's RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous "MZ” genotype with low risk of AATD lung and liver ...

CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

Researchers have developed RNA therapeutics, called micelles, that can delivery chemotherapeutic drugs to metastasized tumors in mouse models.

Apart from carrying the information to encode proteins in, RNA molecules can adopt intricate 2D and 3D structures. Specifically, the same RNA molecule can switch between ON and OFF structures, ...

Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 ...

The RestorAATion-2 trial is ongoing and Wave expects to share multidose data in 2025. "Achieving the first-ever therapeutic RNA editing in humans is a significant milestone for our organization, for ...